Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director departure Appointed director
|
InMed Pharmaceuticals Inc. (INM)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/29/2023 |
10-K
| Annual Report for the period ended June 30, 2023 |
09/29/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
07/24/2023 |
8-K
| Quarterly results |
07/20/2023 |
8-K
| Quarterly results |
06/01/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/25/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
|
"InMed to Participate in Upcoming Virtual Investor Events Vancouver, BC – May 24, 2023 – InMed Pharmaceuticals Inc. , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the Company’ s executive team will be participating in the upcoming virtual investor events: Tribe Public Webinar Date: May 31, 2023 Time: 12:00 PM ET Registration: https://us06web.zoom.us/webinar/register/WN_6ZYkEADVSPOFd3g68IzQsw#/registration Eric A. Adams, CEO of InMed, and Jerry Griffin, VP, Sales and Marketing of BayMedica, will co-host a presentation event titled "Addressing The Increasing Demand For Rare Cannabinoids". Management will be available for a 5-10 minute Q&A session at the end of the presentation. Pleas..." |
|
05/19/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/16/2023 |
4
| HSU ERIC C (Sr. VP, Pre-Clinical Res/Dev) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Unknown transaction of 152 options to buy
@ $0 |
|
05/16/2023 |
4
| MANCINI ALEXANDRA DIANE JANET (Sr VP, Clinical Reg Affairs) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Unknown transaction of 485 options to buy
@ $0 |
|
05/16/2023 |
4
| ADAMS ERIC A (President & CEO) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Unknown transaction of 1,818 options to buy
@ $0 |
|
05/16/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
03/28/2023 |
8-K
| Quarterly results |
03/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
03/09/2023 |
4
| MANCINI ALEXANDRA DIANE JANET (Sr VP, Clinical Reg Affairs) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Unknown transaction of 61 options to buy
@ $0 |
|
03/09/2023 |
4
| HSU ERIC C (Sr. VP, Pre-Clinical Res/Dev) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Unknown transaction of 545 options to buy
@ $0 |
|
03/09/2023 |
4
| ADAMS ERIC A (President & CEO) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Unknown transaction of 545 options to buy
@ $0 |
|
03/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in INMED PHARMACEUTICALS, INC. |
02/09/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
01/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Grove Janet P (Director) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns:
| Granted 840 options to buy
@ $1.78, valued at
$1.5k
|
|
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/16/2022 |
8-K
| Quarterly results |
|
|
|